Avondet
Brant Alan Avondet, Olathe, KS US
Patent application number | Description | Published |
---|---|---|
20130268286 | PROVIDING PROTOCOL VARIANCES FROM STANDARD PROTOCOLS - Systems and method for identifying and providing protocol variances are provided. In embodiments, the method includes referencing an ordered protocol associated with a health condition for a patient. Such an ordered protocol includes a plan for a course of health or medical treatment for the health condition of the patient. A standard protocol that corresponds with the ordered protocol is also referenced. Thereafter, the ordered protocol is compared to the standard protocol to identify at least one protocol variance that indicates a portion of the ordered protocol has been adjusted as compared to the standard protocol. Any identified protocol variances are presented, for example, to a user computing device for display to a user. | 10-10-2013 |
Brant Alan Avondet, Highland, UT US
Patent application number | Description | Published |
---|---|---|
20160063200 | ASSESSING RISKS FOR PROFESSIONALS - Malpractice risk and other risk factors can be associated with online ratings of professionals to assess and categorize malpractice risk and other risk factors for those professionals. Analysis of malpractice risk includes gathering online ratings data for professionals and analyzing the aggregated data in conjunction with malpractice or other risk data and other demographic information of the same or similar professionals to determine statistically significant correlations and algorithms. The process for using these risk algorithms to categorize risk includes aggregating online data for professionals and applying algorithms to categorize the risk of the professionals. | 03-03-2016 |
Marc Avondet, Uetendorf CH
Patent application number | Description | Published |
---|---|---|
20140287433 | MEANS AND METHODS FOR DETERMINING CLOSTRIDIAL NEUROTOXINS - This invention relates to a method of determining presence, amount and/or activity of a clostridial neurotoxin in a sample, the method comprising or consisting of the following steps: (a) bringing said sample into contact with a liposome, said liposome comprising (aa) at least one receptor on its outer surface, said receptor being capable of binding said neurotoxin and comprising or consisting of (i) a glycolipid and (ii) a peptide or protein; and (ab) a substrate in its interior, said substrate (i) being cleavable by the peptidase comprised in said neurotoxin and (ii) generating a detectable signal upon cleavage, said detectable signal preferably being generated by (1) the donor of a FRET pair, said donor exhibiting increased fluorescence upon cleavage by said peptidase, (2) a luminescent compound formed upon said cleavage, or (3) an enzyme formed upon said cleavage; and (b) determining whether an increase in signal occurs as compared to the absence of said sample, wherein such increase is indicative of the presence of said neurotoxin and/or the degree of such increase is indicative of the amount and/or activity of said neurotoxin in said sample. | 09-25-2014 |